All In Biotech

Drug Trial Radar · NCT02633579

Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways

The Role of Induced Phase 3 Contractions in the Control of Hunger and Food Intake

Last checked: Nov 19, 2026Latest source record: Dec 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Oct 2012

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, the investigators will evaluate if the food intake associated with the infusion of erythromycin is caused by the phase 3 contractions or by another yet unknown effect of erythromycin. To obtain this the investigators will use atropine, a muscarinic receptor antagonist, to inhibit the formation of contractions induced by a low dose of erythromycin

Conditions

  • Healthy

Interventions

  • erythromycin lactobionateDrug

    intravenous administration of erythromycin

  • AtropineDrug

    intravenous administration of atropine

  • Erythromycin with atropineDrug

    intravenous administration of erythromycin with saline

  • SalineDrug

    intravenous administration of saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in hunger ratings from time of administration over 6 hoursTime frame: 6 hours after intervention, assessment every 5 minutes

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.